Rodrigo de Oliveira Cavagna, Icaro Alves Pinto, Flávia Escremim de Paula, Gustavo Noriz Berardinelli, Débora Sant'Anna, Iara Santana, Vinicius Duval Da Silva, Eduardo Caetano Albino da Silva, José Elias Miziara, Josiane Mourao, Augusto Antoniazzi, Alexandre Jacinto, Pedro De Marchi, Miguel Angel Molina, Leticia Ferro Leal, Rui Manuel Reis
INTRODUCTION: TP53 is the most frequently mutated gene in lung tumors, but its prognostic role in admixed populations, such as Brazilians, remains unclear. In this study, we aimed to evaluate the frequency and clinicopathological impact of TP53 mutations in non-small cell lung cancer (NSCLC) patients in Brazil. METHODS: We analyzed 446 NSCLC patients from Barretos Cancer Hospital. TP53 mutational status was evaluated through targeted next-generation sequencing (NGS) and the variants were biologically classified as disruptive/nondisruptive, and as truncating/non-truncating...
April 8, 2023: Pathobiology: Journal of Immunopathology, Molecular and Cellular Biology